In contrast, sporadic clinical studies performed with denosumab, a humanized antibody against the central osteoclastogenic factor RANKL, showed that RANKL inhibition may effectively reduce the growth rate of FD lesions, besides reducing pain and bone turn-over markers (for review see [5]). This evidence concerns the gene TNFSF11 and Fabry disease.